Previous reports suggest that β-lap is a competent tumor-selective agent against many NQO1+ solid cancers, such as NSCLC, pancreatic and breast cancers (6, 11, 34–36), while the antitumor effect of this drug in liver cancer is still unknown. The gene discussed is NQO1; the disease is liver cancer.